BioNTech stock has climbed 25% over four days as the German biotech rides a round of cancer treatment success from Summit ...

Today, Benzinga 's options scanner spotted 26 uncommon options trades for BioNTech. This isn't normal. The overall sentiment ...

BioNTech (BNTX) stock traded higher on Tuesday after Jefferies upgraded the COVID-19 vaccine maker to Buy, citing the ...

In a report released yesterday, John Newman from Canaccord Genuity maintained a Buy rating on BioNTech SE (BNTX – Research Report), with ...

The latest flu vaccines are now available, and just like the COVID-19 shots, it's recommended to get the flu shot in ...

Summit Therapeutics acquired rights to ivonescimab outside of China and Australia. With Keytruda sales up around $25 billion ...

Jefferies analyst Akash Tewari upgraded BioNTech SE (BNTX – Research Report) to a Buy today and set a price target of $150.00. The ...

The BioNTech SE ADR BNTX inched 0.06% higher to $123.47 Monday, on what proved to be an all-around great trading session for ...

The company's best days as a top pandemic vaccine supplier might be over, but it still has enough potential to be compelling.

Fintel reports that on September 16, 2024, JP Morgan upgraded their outlook for BioNTech SE - Depositary Receipt () (NasdaqGS ...

The Federal Reserve is widely expected to cut interest rates on Wednesday, following a strong week for stocks. Former ...

The potential of mRNA vaccines was established during the COVID-19 pandemic. Now, a new wave of candidates could soon hit the ...